Sucampo Pharmaceuticals, Inc. is a U.S.-based biopharmaceutical company focused on the development and commercialization of drugs targeting gastrointestinal disorders. Its flagship product, AMITIZA (lubiprostone), was approved by the U.S. FDA in 2006 for chronic idiopathic constipation in adults.
Previously marketed in partnership with Takeda, the collaboration ended in March 2024, after which AMITIZA ceased to be sold or marketed by Takeda.
